Drug profile · INN
trastuzumab emtansine
KADCYLA
trastuzumab emtansine (KADCYLA) is a tubulin inhibitor. Associated with Hoffmann-La Roche.
EMA: approved TGA: approved PMDA: approved Antineoplastic and immunomodulating agents (L01) L01FD03
Patents linked 0
Pipeline programs 15
News articles 0
Drug details — trastuzumab emtansine
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 15
- Data quality
- 0.83
Quick answer
trastuzumab emtansine (KADCYLA) is a tubulin inhibitor. Associated with Hoffmann-La Roche.
Key facts
INN trastuzumab emtansine
Brand KADCYLA
Mechanism Tubulin inhibitor
Target Receptor tyrosine-protein kinase erbB-2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FD03
Originator Hoffmann-La Roche
Mechanism of action
Tubulin inhibitor
Primary target: Receptor tyrosine-protein kinase erbB-2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trastuzumab emtansine?
trastuzumab emtansine (KADCYLA) is a tubulin inhibitor. Associated with Hoffmann-La Roche.
What is the brand name for trastuzumab emtansine?
KADCYLA is a marketed brand name for trastuzumab emtansine. Check FDA Drugs@FDA for the current US label holder and prescribing information.